Combination of targeting gene-viro therapy with recombinant Fowl-pox viruses with HN and VP3 genes on mouse osteosarcoma

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 6, 2013, Pages 767-776

  Zhang, Z Y ^a   Wang, L Q ^b   Fu, C F ^c   Li, X ^d   Cui, Z L ^e   Zhang, J Y ^f   Xue, S H ^g   Sun, N ^h   Xu, F ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e Chinese People's Liberation Army the 65133rd Force of the Political Department   (China)

^f BEIJING HOSPITAL   (China)

^g Northeast Yucai School   (China)

^h GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Gene viro therapy; HN.; Osteosarcoma; Recombinant Fowl pox virus; VP3

Indexed keywords

HN PROTEIN; PROTEIN VP3; PUROMYCIN; SIALIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; FOWLPOX VIRUS; GENE INSERTION; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOSARCOMA; TUMOR GROWTH; VIRAL GENE THERAPY;

ANIMALS; BONE NEOPLASMS; CAPSID PROTEINS; CELL LINE, TUMOR; FOWLPOX VIRUS; GENES, VIRAL; GENETIC THERAPY; HN PROTEIN; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; TRANSFECTION;

EID: 84878588491     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. BRAMWELL VH. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 1997; 24: 561-571.
2. HAYDON RC, LUU HH, HE TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007; 454: 237-246.
3. MEYERS PA, GORLICK R. Osteosarcoma. Pediatr Clin North Am 1997; 44: 973-989.
4. BAO PP, ZHENG Y, WANG CF, GU K, JIN F, LU W. Time trends and characteristics of childhood cancer among children age 0-14 in Shanghai. Pediatr Blood Cancer 2009; 53: 13-16.
5. TSUCHIYA H, KANAZAWA Y, ABDEL-WANIS ME, ASADA N, ABE S, ISU K, SUGITA T, TOMITA K. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 2002; 20: 3470-3477.
6. CORRADI D, WENGER DE, BERTONI F, BACCHINI P, BOSIO S, GOLDONI M, UNNI KK, SIM FH, INWARDS CY. Multicentric osteosarcoma: clinicopathologic and radiographic study of 56 cases. Am J Clin Pathol 2011; 136: 799-807.
7. KAMATH AT, FENG CG, MACDONALD M, BRISCOE H, BRITTON WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999; 67: 1702-1707.
8. DACHS GU, DOUGHERTY GJ, STRATFORD IJ, CHAPLIN DJ. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9: 313-325.
9. AFONSO CL, TULMAN ER, LU Z, ZSAK L, KUTISH GF, ROCK DL. The genome of fowlpox virus. J Virol 2000; 74: 3815-3831.
10. CROSS D, BURMESTER JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006; 4: 218-227.
11. SCHIRRMACHER V, AHLERT T, PROBSTLE T, STEINER HH, HEROLD-MENDE C, GERHARDS R, HAGMULLER E, STEINER HH. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25: 677-696.
12. ZENG J, FOURNIER P, SCHIRRMACHER V. Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction. J Mol Med (Berl) 2002; 80: 443-451.
13. ZENG J, FOURNIER P, SCHIRRMACHER V. Induction of interferon- alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002; 297: 19-30.
14. PIETERSEN A, NOTEBORN HM. Apoptin. Adv Exp Med Biol 2000; 465: 153-161.
15. ZAMARIN D, PALESE P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 2012; 7: 347-367.
16. ZHANG KJ, QIAN J, WANG SB, YANG Y. Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. J Biomed Sci 2012; 19: 20.